A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

BACKGROUND: This phase Ib study evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of pimasertib (MSC1936369B), a MEK1/2 inhibitor, in combination with voxtalisib (SAR245409), a pan-PI3K and mTORC1/mTORC2 inhibitor, in patients with advan...

Descripción completa

Detalles Bibliográficos
Autores principales: Schram, Alison M., Gandhi, Leena, Mita, Monica M., Damstrup, Lars, Campana, Frank, Hidalgo, Manuel, Grande, Enrique, Hyman, David M., Heist, Rebecca S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288157/
https://www.ncbi.nlm.nih.gov/pubmed/30425349
http://dx.doi.org/10.1038/s41416-018-0322-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288157/
https://www.ncbi.nlm.nih.gov/pubmed/30425349
http://dx.doi.org/10.1038/s41416-018-0322-4

Ejemplares similares